Loading…
Employees: 1,961
Size HeiLongJiang ZBD Pharmaceutical (603567.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $705M, the 3045th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥5.01 on 6 Nov 2026.
Performance Over six months the shares fell 29.2%, against -6.1% for the median peer and -16.4% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue fell 82.0% over the last twelve months (peer median +16.1%).
Valuation It trades at 6.3× forward earnings against a peer median of 17.7× (2nd cheapest of 12).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is -25%, so the hurdle is +36 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥286M | CN¥796M | CN¥2.69B | CN¥3.13B | CN¥4.20B |
| Revenue growth | — | -70% | -14% | -26% | — |
| Gross profit | n/a | -CN¥71.4M | CN¥1.40B | CN¥1.24B | CN¥639M |
| EBITDA | n/a | -CN¥1.31B | CN¥774M | CN¥303M | -CN¥108M |
| Net income | -CN¥1.48B | -CN¥1.37B | CN¥438M | CN¥473M | CN¥185M |
| Free cash flow | CN¥198M | CN¥254M | -CN¥1.42M | -CN¥553M | -CN¥679M |
| Capital expenditure | CN¥30.1M | CN¥68.5M | CN¥189M | CN¥95.1M | CN¥404M |
| Total debt | CN¥3.14B | CN¥3.14B | CN¥3.36B | CN¥3.26B | CN¥3.05B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603567.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.8% | -5.9% | 10th highest of 21 |
| 6-month return | -29.2% | -6.1% | 3rd lowest of 21 |
| Distance from 52-week high | -58.1% | -26.3% | 2nd lowest of 21 |
| Revenue growth (TTM) | -82.0% | +16.1% | lowest of 17 |
| Forward P/E | 6.3× | 17.7× | 2nd cheapest of 12 |
| Growth the price implies (Req g, 7 yrs) | 10.5% | 0.0% | 3rd most demanding of 8 |
| Growth delivered (Del g) | -25.1% | +7.9% | lowest of 8 |
| Hurdle (Req g minus delivered) | +35.6 pp | -0.7 pp | most demanding of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $705M | -29% | -82% | n/a | 6.3× | 10.5% | -25.1% |
| Hainan Haiyao 000566.SZ | China | $710M | -19% | -18% | -50% | n/a | n/a | n/a |
| Yabao Pharmaceutical 600351.SS | China | $711M | -3% | -3% | 16% | n/a | -7.5% | -2.8% |
| Bliss GVS Pharma BLISSGVS.NS | India | $698M | +126% | +21% | 15% | n/a | 37.0% | +10.1% |
| Philogen PHIL.MI | Italy | $694M | -7% | +295% | 79% | 32.5× | n/a | n/a |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $716M | -24% | +5% | -30% | 64.3× | n/a | n/a |
| Sagimet Biosciences SGMT | United States | $693M | +28% | n/a | n/a | n/a | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $692M | -16% | +23% | 11% | 88.2× | 10.3% | +7.9% |
| Achieve Life Sciences ACHV | United States | $692M | +29% | n/a | n/a | n/a | n/a | n/a |
| Zevra Therapeutics ZVRA | United States | $690M | +4% | +75% | 31% | 11.8× | 0.0% | +51.6% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -33% | -36% | 36% | 9.1× | n/a | n/a |
| Ardelyx ARDX | United States | $724M | -58% | +18% | -8% | 225.1× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 11% | 36.8× | 41.4% | +11.2% |
| Arbutus Biopharma ABUS | United States | $724M | -16% | +1,079% | 81% | n/a | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $725M | +4% | +26% | 61% | 3.3× | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 9% | 15.2× | n/a | n/a |
| Nuvectis Pharma NVCT | United States | $683M | +79% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $682M | -5% | +13% | 4% | n/a | n/a | n/a |
| Cullinan Therapeutics CGEM | United States | $728M | -22% | n/a | n/a | n/a | n/a | n/a |
| Earth 4985.T | Japan | $682M | +6% | +6% | 4% | 17.7× | -2.5% | -1.8% |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $678M | -6% | +10% | 19% | 12.7× | -2.4% | +6.4% |